Renewal of WHO-GMP Certificate

Pars Isotope has successfully renewed its WHO-GMP certificate from the Iran Food and Drug Administration.

As the sole entity responsible for the production and supply of diagnostic and therapeutic radiopharmaceuticals in Iran, Pars Isotope has successfully renewed its WHO-GMP certification from the Iran Food and Drug Administration (IFDA). This renewal reaffirms the company’s unwavering adherence to the highest international standards in radiopharmaceutical manufacturing processes, as well as the preservation of impeccable product quality in accordance with the World Health Organization (WHO) guidelines.

Owing to their unique nature and application in the diagnosis and treatment of various cancers and diseases, radiopharmaceuticals demand an exceptional level of precision, safety, and quality. The renewal of this certificate stands as a definitive validation of Pars Isotope’s accomplished performance in domains such as: maintaining and advancing technical and radiation infrastructure, rigorous execution of quality control procedures, sustained documentation and traceability, upholding elevated staff training standards, and ensuring consistent, reliable product manufacturing.

Through this certificate renewal, we demonstrate our unwavering resolve to deliver products aligned with the most stringent global standards. Building upon this achievement, we strive to attain developmental objectives, expand our product portfolio, and advance public health within the community.